Driehaus Capital Management Adds $10M in Edgewise Therapeutics, Inc. ($EWTX)

Driehaus Capital Management has boosted its stake in Edgewise Therapeutics, Inc. (NasdaqGS: EWTX), adding 286,749 shares according to its latest 13F filing with the SEC. This brings Driehaus's total holdings to 4,477,942 shares, valued at approximately $156 million as of the end of the reporting period.

What Changed in Driehaus Capital's Edgewise Position

Driehaus Capital Management increased its investment in Edgewise Therapeutics by 6.8%, acquiring an additional 286,749 shares. The firm now holds 4,477,942 shares in total, up from 4,191,193 shares previously. This adjustment reflects a continued confidence in the company's prospects.

Other Institutional Activity in Edgewise Therapeutics

Several other institutional investors have also been active in Edgewise Therapeutics. Paradigm Biocapital Advisors LP increased its stake by 823,828 shares, now holding 7,365,038 shares valued at around $232 million. Meanwhile, Janus Henderson Group PLC added 1,348,706 shares to reach a total of 5,915,556 shares worth about $186 million. On the other hand, BlackRock, Inc. trimmed its position by 157,585 shares, ending with 6,472,991 shares valued at $204 million.

Edgewise Therapeutics Stock Snapshot

Shares of Edgewise Therapeutics traded at $34.83, with a market capitalization of roughly $3.75 billion. The company, which is not yet profitable, has a forward P/E ratio that is not meaningful due to its negative earnings per share. Edgewise's stock has seen a 52-week low of $12.15 and a high of $40.77. The stock's 50-day moving average is $33.62, while the 200-day moving average is $25.58. The company maintains a strong current ratio of 22.61 and a debt-to-equity ratio of 0.77.

Recent Earnings

Edgewise Therapeutics is expected to announce its next earnings on August 6, 2026. The company is currently not profitable, with a negative return on equity of -38.1% and no net margin.

Insider Buying and Selling at Edgewise Therapeutics, Inc.

Recent insider transactions include Joanne Donovan, the Chief Medical Officer, who sold 50,000 shares at $38.57 on May 5, 2026. On the same day, Donovan also purchased 50,000 shares at $7.08. Additionally, Jonathan Fox acquired 339 shares on April 1, 2026.

Analysts Set New Price Targets

On June 2, 2026, HC Wainwright & Co., RBC Capital, and Wedbush all maintained their 'buy' ratings for Edgewise Therapeutics, with price targets set at $45, $48, and $52, respectively. The stock has a consensus 'buy' recommendation with an average target price of $46.08, based on 12 analyst opinions.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., headquartered in Boulder, Colorado, is a biopharmaceutical company focused on developing treatments for muscle disorders. Its leading product candidate, sevasemten, is in Phase II clinical trials targeting dystrophinopathies like Duchenne and Becker muscular dystrophy. The company also works on other therapies for cardiac disorders and heart failure. Founded in 2017, Edgewise is led by CEO Dr. Kevin Koch and employs approximately 154 people.

Bottom Line

Driehaus Capital Management's increased stake in Edgewise Therapeutics underscores its positive outlook on the company's future. Investors track such 13F filings to gauge institutional confidence and potential trends in the stock. However, it's important to remember that these filings are historical and may not reflect current positions.